Phase 2 Trial of BX004, Phage Therapy for Bacterial Infections, Advancing

Phase 2 Trial of BX004, Phage Therapy for Bacterial Infections, Advancing
4.4
(8)

A Phase 2 clinical trial assessing the safety and efficacy of BX004 — BiomX’s phage therapy candidate for Pseudomonas aeruginosa infections in people with cystic fibrosis (CF) — remains on track to have results by the end of this year, the company announced.

While this timeline had been announced in a prior update, BiomX added that BX004 is now its selected investigational treatment for CF.

P. aeruginosa is the most common bacteria in lung infections and severe lung disease in people with CF. While antibiotics are usually the mainstay for such infections, certain bacteria develop ways of resisting standard antibiotics, making treatment difficult.

BiomX has developed a BOLT (BacteriOphage Lead to Treatment) platform that uses phages — viruses, or a virus cocktail, that can infect and kill bacterial cells — instead of antibiotics as bacteria-targeting therapies. BOLT was designed to rapidly develop phages (within six to eight weeks) targeting specific bacteria in a manner tailored to a given patient.

The process begins with isolating a person’s bacterial strain, followed by optimizing and producing the therapy for testing in clinical trials.

According to BiomX, studies conducted in the lab showed that BX004 is active against antibiotic-resistant strains of P. aeruginosa and can penetrate biofilm — slimy layers of microorganisms that stick to wet surfaces and protect bacteria from antibiotics and the host’s immune response.

Phage are “natural predators of bacteria,” and “specific to particular bacterial species or strains, targeting and killing them without disrupting other neighboring, potentially beneficial, bacteria,” the company states on its website.

“2020 was a tremendous year of growth for BiomX, as we expanded our pipeline with programs in cystic fibrosis and atopic dermatitis [eczema], both designed to address unmet medical needs,” said Jonathan Solomon, the company’s CEO.

BiomX reported in an April presentation that its Phase 2 proof-of-concept trial was testing BX004, as a nebulized therapy, against a placebo in up to 40 CF patients with chronic P. aeruginosa infections. Treatment would be given for seven to 10 days, with the efficacy of this phage combination evaluated through changes in bacterial counts, and measures of lung function and quality of life.

The company is also conducting clinical trials of phage-based treatment candidates for acne, inflammatory bowel disease, and primary sclerosing cholangitis.

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York.
Total Posts: 40
José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has studied Biochemistry also at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario, in London, Ontario. His work ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
×
Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York.
Latest Posts
  • treatment burden, adherence
  • Pulsehaler

How useful was this post?

Click on a star to rate it!

Average rating 4.4 / 5. Vote count: 8

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?